The euro area’s top stock benchmark is welcoming a rare entry by a biotech firm, promising to ignite fresh interest in a ...

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds ...

CRISPR Therapeutics AG (NASDAQ: CRSP) is one of the best emerging technology stocks to buy right now. On September 3, Bank of ...

While the telephone brought comfort, smartphones changed lives. While factories powered economies, artificial intelligence ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...

Cathie Wood is known for seizing opportunities. The founder of Ark Invest doesn't worry when one of the stocks she's invested ...

CRISPR Therapeutics AG ( NASDAQ: CRSP) H.C. Wainwright 27th Annual Global Investment Conference September 8, 2025 4:30 PM EDT ...

Discover Beam Therapeutics’ gene editing advances, targeting lifelong cures for serious diseases with precision base editing.

The data center equipment supplier delivers a lesson on how to crush analyst estimates. It easily beat on both the top and bottom lines in the opening quarter of its fiscal 2026, while posting ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $5.0, a high estimate of $6.00, and a low estimate of $4.00. Witnessing a positive shift, the current average ...

Investors in athletic apparel maker Lululemon Athletica are seeing red this morning after the company reported its second-quarter fiscal 2025 results. While the athleisure brand surpassed Wall Street ...